Smyczńyska Joanna, Cyniak-Magierska Anna, Stasiak Magdalena, Karbownik-Lewińska Małgorzata, Lewiński Andrzej
Department of Endocrinology and Metabolic Diseases, Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland.
Neuro Endocrinol Lett. 2014;35(5):335-41.
The main clinical manifestations of autoimmune thyroid diseases are Graves' disease (GD) and Hashimoto's thyroiditis (HT). Graves' disease is the cause of most cases of hyperthyroidism in childhood. Indications for radical therapy (surgery or 131I treatment) in children are still a matter of discussion, as sustained (sometimes very long) remission of GD is possible, while the radical therapy almost always leads to hypothyroidism. Spontaneous evolution from GD with hyperthyroidism to HT with hypothyroidism may also be observed.
The aim of the study was to analyze the clinical course of 6 cases of hyperthyroid girls with GD in whom a normalization of previously increased autoantibodies against thyrotropin (TSH) receptor (anti-TSHR) was observed together with a significant increase in autoantibodies against thyroid peroxidase (anti-TPO) and thyroglobulin (anti-Tg), with concomitant hypo- or euthyroidism but no recurrence of hyperthyroidism.
Patients' age at diagnosis ranged from 5.0 to 16.5 years. Two (2) patients had Turner syndrome, another one (1), diabetic, was on insulin therapy.
In all the girls, antithyroid drugs were administered and euthyroid state was achieved during the first 2.0-3.5 months of the treatment. Mild side effects were observed in only one case. The therapy was continued up to 1.5-4.0 years. Relapses during the therapy were observed in 2 cases. Up to now, no relapses have been observed for 0.5-7.5 years since the therapy withdrawal in 5 patients (1 patient was lost to follow-up), 2 patients are currently treated with levothyroxine due to hypothyroidism.
It seems that the prolonged pharmacotherapy with antithyroid drugs, followed by observation after remission of hyperthyroidism, may be an appropriate therapeutic option at least in some children with GD as they can be cured without radical therapy and the potential risks of such treatment.
自身免疫性甲状腺疾病的主要临床表现为格雷夫斯病(GD)和桥本甲状腺炎(HT)。格雷夫斯病是儿童期大多数甲亢病例的病因。儿童根治性治疗(手术或¹³¹I治疗)的指征仍存在争议,因为GD有可能实现持续(有时非常长)缓解,而根治性治疗几乎总是导致甲状腺功能减退。也可能观察到从甲亢的GD自发演变为甲减的HT。
本研究的目的是分析6例患有GD的甲亢女孩的临床病程,这些女孩之前针对促甲状腺素(TSH)受体的自身抗体(抗TSHR)升高已恢复正常,同时针对甲状腺过氧化物酶(抗TPO)和甲状腺球蛋白(抗Tg)的自身抗体显著增加,伴有甲状腺功能减退或甲状腺功能正常,但无甲亢复发。
诊断时患者年龄在5.0至16.5岁之间。两名患者患有特纳综合征,另一名糖尿病患者接受胰岛素治疗。
所有女孩均接受了抗甲状腺药物治疗,并在治疗的前2.0 - 3.5个月内实现了甲状腺功能正常。仅1例观察到轻微副作用。治疗持续了1.5 - 4.0年。治疗期间2例出现复发。截至目前,5例患者(1例失访)在停药后0.5 - 7.5年未观察到复发,2例患者因甲状腺功能减退目前正在接受左甲状腺素治疗。
似乎对于抗甲状腺药物进行长期药物治疗,随后在甲亢缓解后进行观察,至少对于一些GD患儿可能是一种合适的治疗选择,因为他们无需根治性治疗及其潜在风险即可治愈。